Although an elevation in urine zinc output is known to occur in cancer
patients, little attention has been paid to urinary copper excretion.
We have investigated urinary zinc, copper and neopterin, an index of
systemic immune activation, in 40 patients with cancer. As expected, u
rinary zinc and neopterin were significantly higher in the patients th
an in the reference group (2.04 +/- 1.51 vs 0.56 +/- 0.37 mmol/mol cre
atinine, p < 0.001 and 453 +/- 510 vs 181 +/- 59 mumol/mol creatinine,
p < 0.01, respectively). Urinary copper was also significantly higher
in cancer patients (112 +/- 124 vs 33 +/- 20 mumol/mol creatinine, p
< 0.01). A significant correlation between urinary zinc and neopterin
(rs = 0.4881, p < 0.01), copper and neopterin (rs = 0.3296, p < 0.05)
and zinc and copper (rs = 0.5714, p < 0.001) was observed. We conclude
that similarly to zinc, urinary copper excretion is elevated in cance
r patients. Elevated excretion of both trace elements appears to invol
ve similar mechanisms and may be linked with systemic immune response.